Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mitchison, D A
Right arrow Articles by Grosset, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mitchison, D A
Right arrow Articles by Grosset, J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 44:757-774 (1988)
© 1988 The British Council

research-article

New antibacterial drugs for the treatment of mycobacterial disease in man

D A Mitchison, G A Ellard and J Grosset

Department of Bacteriology, Royal Postgraduate Medical School London
Laboratory for Leprosy and Mycobacterial Research, National Institute for Medical Research Mill Hill, London
Department of Bacteriology and Virology, Pitie-Salpetriere School of Medicine Paris, France

Abstract

New chemotherapeutic drugs are needed for the treatment of mycobacterial infections to expand the number of available drugs in the face of increasing drug-resistance, to shorten the period of treatment, to allow effective treatment of Mycobacterium avium—intracellulare—scrofulaceum (MAIS) complex infections and, of greatest importance for tuberculosis, to facilitate fully supervised, widely intermittent regimes. Several new rifamycin derivatives are being explored and appear likely to achieve many of these aims. The fluorinated quinolones are the most promising new drugs for the treatment of leprosy. However, the most active quinolones are only just effective in tuberculosis at current dose levels. The ß-lactam group and inhibitors of dihydrofolate reductase are only at the stage of in vitro study


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
N. N. Bock, T. R. Sterling, C. D. Hamilton, C. Pachucki, Y.-C. Wang, D. S. Conwell, A. Mosher, M. Samuels, and A. Vernon
A Prospective, Randomized, Double-Blind Study of the Tolerability of Rifapentine 600, 900, and 1,200 mg Plus Isoniazid in the Continuation Phase of Tuberculosis Treatment
Am. J. Respir. Crit. Care Med., June 1, 2002; 165(11): 1526 - 1530.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.